The independent data safety monitoring committee has cleared VBL Therapeutics to continue a phase 3 trial of VB-111 in ovarian cancer patients. VBL got the green light after the committee looked at unblinded overall survival (OS) data for the second pre-planned interim analysis.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,